New Bone-Boosting shot tested for first time in humans
NCT ID NCT07178327
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage study tests a new injectable drug called LYN101 in 44 people. First, healthy volunteers get a single dose to check safety. Then, postmenopausal women with low bone mass get multiple doses to see how the drug affects bone turnover markers. The main goal is safety, not yet proof that it prevents fractures.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LYN101 (injectable drug)
- What this could lead to
- If successful, this could point toward a new treatment to strengthen bones and reduce fracture risk in osteoporosis.
- What could go wrong
- This is a very early Phase 1 trial with only 44 participants, focused on safety. It is too small and early to know if LYN101 will actually help bones or be safe long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPOROTIC FRACTURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Sixth People's Hospital
Shanghai, China
-
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, 233060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Dried plums may strengt hen bones in older women
- Exercise may cut fall risk in osteoporosis
- Could a simple exercise program strengthen bones without drugs?
- Blood marker may uncover fracture risk hidden from bone scans
- Could adding a second drug boost bone strength in osteoporosis?
- Can group exercise help fragile bones? new study aims to find out